ArticleImmunogenetics2015
Diversity in the Toll-like receptor genes of the Tasmanian devil (Sarcophilus harrisii).
Article in Immunogenetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Adaptive Immunity in Marsupials.Journal of experimental zoology. Part A, Ecological and integrative physiology · 2026Review
- A Guide for Developing Demo-Genetic Models to Simulate Genetic Rescue.Evolutionary applications · 2025Article
- Spatial variation in toll-like receptor diversity in koala populations across their geographic distribution.Immunogenetics · 2024Article
- Restoring faith in conservation action: Maintaining wild genetic diversity through the Tasmanian devil insurance program.iScience · 2022Article
- Annotation of immune genes in the extinct thylacine (Thylacinus cynocephalus).Immunogenetics · 2021Article
- Toll-Like Receptor Expression Profiles in Koala (Animals : an open access journal from MDPI · 2021Article
- Article
- Genetic diversity of toll-like receptor genes in the vulnerable Chinese egret (Egretta eulophotes).PloS one · 2020Article
- Adaptive genetic diversity and evidence of population genetic structure in the endangered Sierra Madre Sparrow (Xenospiza baileyi).PloS one · 2020Article
- Review
- Lessons learnt from the Tasmanian devil facial tumour regarding immune function in cancer.Mammalian genome : official journal of the International Mammalian Genome Society · 2018Review
- Transcriptome sequencing of the long-nosed bandicoot (Perameles nasuta) reveals conservation and innovation of immune genes in the marsupial order Peramelemorphia.Immunogenetics · 2018Article
- Coevolution of the Toll-Like Receptor 4 Complex with Calgranulins and Lipopolysaccharide.Frontiers in immunology · 2018Article
- The identification of immune genes in the milk transcriptome of the Tasmanian devil (Sarcophilus harrisii).PeerJ · 2016Article
- Identification and analysis of divergent immune gene families within the Tasmanian devil genome.BMC genomics · 2015Article
- SNP marker discovery in koala TLR genes.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Tasmanian devil is an endangered marsupial species that has survived several historical bottlenecks and now has low genetic diversity. Here we characterize the Toll-like receptor (TLR) genes and their diversity in the Tasmanian devil. TLRs are a key innate immune gene family found in all animals. Ten TLR genes were identified in the Tasmanian devil genome. Unusually low levels of diversity were found in 25 devils from across Tasmania. We found two alleles at TLR2, TLR3 and TLR6. The other seven genes were monomorphic. The insurance population, which safeguards the species from extinction, has successfully managed to capture all of these TLR alleles, but concerns remain for the long-term survival of this species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.